Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


NMS eligibility criteria to be expanded following child asthma enquiry

NHSE&I is widening the eligibility criteria for the NMS to allow guardians to provide consent on a patient's behalf, following an enquiry into the management of chronic asthma.

The Healthcare Safety Investigation Branch (HSIB) – an independent investigatory body funded by the Department of Health and Social Care (DH) – published a report today (May 5), listing its recommendations to improve the management of chronic asthma in children aged 16 or under.

The report primarily focuses on the learnings from a case of a child who experienced a “near-fatal asthma attack” when he was five.

Too young to give “informed consent” 

In the case of the five-year-old child, HSIB heard during the investigation that he was too young to “provide informed consent” and was therefore not eligible for medicines use reviews (MURs) or the new medicines service (NMS).

Medicines adherence was an issue, in that the child was not being given the corticosteroid medication he had been prescribed “in line with the prescriber’s instructions”, according to the HSIB report.

“The community pharmacist told the investigation that had the child been eligible for an MUR, the irregularities in collecting medicines may well have been identified, with appropriate feedback provided to the prescriber,” HSIB wrote in the report.

The pharmacy was also not monitoring the child’s adherence to medication, due to “minimal information being available to it”.

“The investigation heard that if community pharmacists could edit the summary care record (SCR), they could upload information such as uncollected prescribed medicines,” according to the report.

MURs were decommissioned in April this year and replaced with structured medication reviews (SMRs), which are completed by GP or primary care network pharmacists.

The HSIB said that, following its investigation, NHS England and NHS Improvement (NHSE&I) “plans to make clarifications that children should be considered eligible for SMRs and the NMS, even if too young to consent themselves”.

NMS service specification to be amended

HSIB said that NHSE&I will amend the NMS’s service specification and accompanying guidance and toolkit “to reinforce that ‘the service can be offered to younger children involving their guardians as well as to older patients involving their carers where appropriate’”.

Pharmacists should continue to follow the latest guidance before the updates are issued, NHSE&I told C+D today.

Commenting on the HSIB report, an NHSE&I spokesperson said: “The NHS is already implementing the recommendations of the report with improved asthma care at the heart of the NHS long-term plan, which committed to improving asthma outcomes for children and young people”.

A Pharmaceutical Services Negotiating Committee spokesperson told C+D today that any change to the NMS service specification will be negotiated with NHSE&I and the DH.

*This article was updated after publication following extra information from PSNC

Pharmacy teams are aptly placed to support correct inhaler technique and to identify any issues with compliance or adherence. Read C+D’s clinical article on the importance of “going back to basics” with good inhaler technique in younger patients.

Will expanding the NMS eligibility criteria help your patients with asthma?

Related Content


Pharmacy Manager
Newquay, Cornwall
£ Competitive

Apply Now
Latest News & Analysis
See All



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts